Company intelligence
As of June 25, 2026, Ollin Biosciences has raised at least $330M in equity across 1 sourced funding round.
Clinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
Ollin Biosciences is a clinical-stage biotech developing drugs for vision-threatening eye diseases.[1] The company was established in 2023 and in-licenses and develops its drug candidates.[1] Its lead drug, OLN324, is a VEGF/Ang2 bispecific antibody for diabetic macular edema and wet age-related macular degeneration.[1] OLN324 was discovered by and is being developed with China's Innovent Biologics, which calls it IBI324.[1] In the 164-patient JADE study, OLN324 was compared head to head with Roche's Vabysmo (faricimab).[1] After an End-of-Phase 2 meeting with the FDA, Ollin plans to start global Phase 3 trials of OLN324 in the second half of 2026.[1] A second candidate, OLN102, targets thyroid eye disease and Graves' disease and was discovered by VelaVigo.[1] Cariad Chester of TCGX joined the board.[1]
Is something wrong on this page?
Ollin Biosciences is a biotech company, based in Chicago, Illinois, USA, founded 2023.
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Jun 25, 2026 | Series B | $330M | — | Crunchbase NewsPulse story | |
| May 14, 2026 | Funding roundnot counted | $156.2M | — | — | SEC EDGAR Form D |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
On June 24, 2026, Ollin announced an oversubscribed $330 million Series B co-led by TCGX and founding investor ARCH Venture Partners.[1]
Ollin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.
Ollin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.
On June 24, 2026, Ollin announced an oversubscribed $330 million Series B co-led by TCGX and founding investor ARCH Venture Partners.[1]
Jason Ehrlich is co-founder and CEO.[1]
Ollin Biosciences is a clinical-stage biotech developing drugs for vision-threatening eye diseases.[1]
Ollin Biosciences has raised at least $330M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $330M Series B in June 2026, reported by Crunchbase News. Debt financing, tender offers and secondary sales are not counted.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.
